Skip to main content
Erschienen in: Supportive Care in Cancer 10/2009

01.10.2009 | Original Article

Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center

verfasst von: Lincy S. Lal, Donna L. Gerber, Jason Lau, William Dana

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2009

Einloggen, um Zugang zu erhalten

Abstract

Objectives

This is a retrospective observational study evaluating hypersensitivity reactions captured by an electronic medical record (EMR) system for weekly paclitaxel infusions.

Materials and methods

The study evaluates the demographics, co-morbidities, premedications, chemotherapy agents, and postmedications of patients reporting a hypersensitivity reaction to weekly infusions of paclitaxel at a major cancer center, from June 2006 to December 2007. Data were analyzed using descriptive statistics and logistic regression. P values <0.05 were considered significant.

Results

There were 51 hypersensitivity reactions in 36 patients during this time period that were documented in the allergy section of the EMR. Reactions occurred in patients with an average age of 55 years (SD = 10.77); 47 (92%) of the reactions occurred in females, and 42 (82%) of the reactions occurred with orders on the breast medical/surgical service. Thirty-two (63%) reactions occurred with either the first or second dose of weekly paclitaxel infusion. The most common premedication was dexamethasone (50 infusions), followed by diphenhydramine (18 infusions), and cimetidine (14 infusions). Thirty-three (65%) infusions had only one premedication. Postreaction, 41 (80%) cases had diphenhydramine and 30 (59%) cases had hydrocortisone administered prior to restarting the infusion. Logistic regression analysis did not indicate any relationship between history of previous allergies, hypertension, coronary disease, or chronic obstructive pulmonary disease and the number of premedications.

Conclusions

The results indicate that there is substantial variability in the type and number of premedications utilized in the management of paclitaxel hypersensitivity reactions. Interventions are needed to decrease the rate of hypersensitivity reactions from weekly paclitaxel infusions.
Literatur
1.
Zurück zum Zitat Akerly W, Sikov WM, Cummings F et al (1997) Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer. A preliminary report. Semin Oncol 24:87–90 Akerly W, Sikov WM, Cummings F et al (1997) Weekly high-dose paclitaxel in metastatic and locally advanced breast cancer. A preliminary report. Semin Oncol 24:87–90
2.
Zurück zum Zitat Chang AY, Boros L, Asbury R et al (1997) Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancers. Semin Oncol 24:69–71 Chang AY, Boros L, Asbury R et al (1997) Dose-escalation study of weekly 1-hour paclitaxel administration in patients with refractory cancers. Semin Oncol 24:69–71
6.
Zurück zum Zitat Lau DHM, Ryu J, Gandara D et al (1999) Concurrent twice weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol 9:117–120PubMed Lau DHM, Ryu J, Gandara D et al (1999) Concurrent twice weekly paclitaxel and thoracic irradiation for stage III non-small cell lung cancer. Semin Radiat Oncol 9:117–120PubMed
9.
Zurück zum Zitat National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute, Bethesda National Cancer Institute (2006) Common terminology criteria for adverse events v3.0 (CTCAE). National Cancer Institute, Bethesda
11.
Zurück zum Zitat Rowinsky EK, Onetto N, Canetta RM et al (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–662PubMed Rowinsky EK, Onetto N, Canetta RM et al (1992) Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol 19:646–662PubMed
13.
Zurück zum Zitat Sparano JA, Wang M, Martino D et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–671PubMedCrossRef Sparano JA, Wang M, Martino D et al (2008) Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358:1663–671PubMedCrossRef
14.
Zurück zum Zitat University of Texas M. D. Anderson (2008) Paclitaxel. Lexi-Comp ONLINE, Hudson University of Texas M. D. Anderson (2008) Paclitaxel. Lexi-Comp ONLINE, Hudson
15.
Zurück zum Zitat Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reaction from taxol. J Clin Oncol 7:1263–1268 Weiss RB, Donehower RC, Wiernik PH et al (1990) Hypersensitivity reaction from taxol. J Clin Oncol 7:1263–1268
16.
Zurück zum Zitat Zidan J, Hussein O, Abzah A et al (2008) Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. Med Oncol 25:274–278PubMedCrossRef Zidan J, Hussein O, Abzah A et al (2008) Oral premedication for the prevention of hypersensitivity reactions to paclitaxel. Med Oncol 25:274–278PubMedCrossRef
Metadaten
Titel
Retrospective evaluation of weekly paclitaxel hypersensitivity reactions reported utilizing an electronic medical record system at a tertiary cancer center
verfasst von
Lincy S. Lal
Donna L. Gerber
Jason Lau
William Dana
Publikationsdatum
01.10.2009
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 10/2009
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0588-4

Weitere Artikel der Ausgabe 10/2009

Supportive Care in Cancer 10/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.